Browsing Tag
Kirkland & Ellis
6 posts
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
FORVIA agrees to sell Interiors unit to Apollo Funds for €1.8bn in IGNITE strategy push
FORVIA to sell Interiors to Apollo at 3.1x EBITDA. The €1.82bn deal cuts debt by €1bn but reveals how cheaply European suppliers must now sell scale.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
Antin Infrastructure Partners buys Apollo-backed Sapphire Gas Solutions as US grid gaps drive CNG and LNG demand
Antin Infrastructure Partners acquires Sapphire Gas Solutions from Apollo funds. Why distributed CNG and LNG infrastructure is the US energy reliability play. Read more.
KKR doubles down on Enilive with €587.5m—What’s behind the move?
KKR, a leading global investment firm, has strengthened its presence in Enilive by acquiring an additional 5% stake…
ABC technologies announces £1.8bn acquisition of TI Fluid Systems
ABC Technologies has announced a landmark transaction: the acquisition of TI Fluid Systems for £1.83 billion. This transformative…